Approved for use through 11/30/2008. ONB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Pacework Reduction Act of 1995, no persons are required to respond to a collection of information unless it diseases a walf OMR profit number.

Substitute for form 1449A/PTO				Complete if Known		
80	DSIRULE FOR TORM 1449AVP TO			Application Number	10/665,111	
	NFORMATION DISC	ı ns	HIDE	Filing Date	September 16, 2003	
	STATEMENT BY APP			First Named Inventor	Schendel et al.	
	STATEMENT BY APP	LIC	ANI	Art Unit	1643	
(Use as many sheets as necessary)				Examiner Name	Karen A. Canella	
Sheet	1	of	2	Attorney Docket Number	1406/468	

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.	Number - Kind Code <sup>2 (Fánceso)</sup>	MM-DD-YYYY	Applicant of Cited Document		
		US-				
	Γ	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-	***************************************			
		US-				
		US-				
		US-				
		US-				
		US-			The state of the s	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
	1	WO1997/04802	02-13-1997	Pac. NW Cancer Found.			
	2	WO1998/33527	08-06-1998	Cohen			
						_	

Date

Examiner

by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is equired by 37 CPR 1.97 and 1.98. The information is required to obtain or mean a benefit by the public which is to file (and by the USPTO of process) an application. Confidentiality is powered by 58 U.S. C. 122 and 37 CPR 1.14. This collection is estimated to liste 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will very depending upon the left of the complete the form and/or support of the complete the complete the form and/or support of the complete the complete the form and/or support of the complete the compl

PTO/SB/08b (10-08)
Approved for use through 11/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respo

Substitu	te for form 1449B/PTO			Complete if Known		
				Application Number	10/665,111	
INF	ORMATION DISC	CLOS	SURF	Filing Date	September 16, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Schendel et al.	
				Art Unit	1643	
	(Use as many sheets as neo	cessary)		Examiner Name	Karen A. Canella	
Sheet 2 of 2		2	Attorney Docket Number	1406/468		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	3	Boczkowski et al., Induction of Tumor Immunity and Cytotoxic T Lymphocyte Responses Using Dendritic Cells Transfected with Messenger RNA Amplified from Tumor Cells. Cancer Research. Vol. 60 pgs.:1028-1034 (2000).				
	4	Heiser et al., Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro. The Journal of Immunology. Vol. 164, No. 10 pgs.:5508-5514 (2000).	-			
	5	Nair et al., Induction of Carcinoembryonic Antigen (CEA)-Specific Cytotoxic T-Lymphocyte Responses In Vitro Using Autologous Dendritic Calis Loaded with CEA Peptide or CEA RNA In Patients with Metastatic Malignancies Expressing CEA. International Journal of Cancey. Vol. 82 ps;s12-124 (1999).				
	6	Nair, S.K., et al., Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. <u>Nature</u> <u>Biotechnology</u> , Vol. 16, No. 4 pgs.:364-369 (1998).				
	7	Official Action corresponding to Japanese Patent Application No. JP 2002-573045 dated November 18, 2008.				

Examiner	Date
Pignature	1 2 1
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINENCE install a reservation consistence, wementer or not classion is an usual assessment with a merit way. A service as a service of the consistence of the country of the consistence of the country of the consistence of the country of the co This collection on inclination is required by a CPT Let and in Lab. This immediate is required by a common or collection is estimated to the lab (2007) to Let a CPT L on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.